Published in JAMA on June 09, 1999
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med (2001) 4.15
Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 3.49
Estrogen and coronary heart disease in women. JAMA (1991) 3.17
Body mass definitions of obesity: sensitivity and specificity using self-reported weight and height. Epidemiology (1990) 2.65
Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA (1983) 2.57
Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA (1993) 2.28
Medical conditions associated with driving cessation in community-dwelling, ambulatory elders. J Gerontol (1993) 2.12
Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev (1985) 1.95
Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care (1998) 1.83
Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. The CHS Collaborative Research Group. Circulation (1992) 1.79
Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrob Agents Chemother (1990) 1.74
A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev (1994) 1.64
Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol (1997) 1.52
Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA (1995) 1.47
Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab (1996) 1.41
Diabetes mellitus and other cardiovascular risk factors in an elderly population. Age Ageing (1990) 1.38
Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-L-methionine. Biochem J (1991) 1.32
Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with alpha-difluoromethylornithine cure murine malaria. Proc Natl Acad Sci U S A (1989) 1.30
Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med (1993) 1.26
Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res (1992) 1.25
Macronutrient intakes among adult Hispanics: a comparison of Mexican Americans, Cuban Americans, and mainland Puerto Ricans. Am J Public Health (1995) 1.14
Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr (1991) 1.12
Predictors of menopausal hot flashes. J Womens Health (1998) 1.10
Morbidity as a focus of preventive health care in the elderly. Epidemiol Rev (1988) 1.08
Aging and total cholesterol levels: cohort, period, and survivorship effects. Am J Epidemiol (1992) 1.06
Benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med (1988) 1.06
Bis(benzyl)polyamine analogs as novel substrates for polyamine oxidase. J Biol Chem (1990) 1.05
Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol (2001) 1.05
Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta- carotene, lycopene, alpha-tocopherol, and selenium. Cancer Epidemiol Biomarkers Prev (1995) 1.03
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol (1996) 1.00
Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res (1990) 1.00
Factors associated with determinants of sexual functioning in midlife women. Maturitas (2006) 0.97
Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res (1994) 0.96
Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med (1993) 0.94
Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci (1998) 0.90
Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. Photodermatol Photoimmunol Photomed (1992) 0.90
Ethnic differences in cancer mortality trends in the US, 1950-1992. Ethn Health (2001) 0.90
Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites. Am J Epidemiol (1992) 0.90
Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation (1993) 0.90
Smoking and cardiovascular mortality in women. Am J Epidemiol (1983) 0.89
Cancer mortality and lipid and lipoprotein levels. Lipid Research Clinics Program Mortality Follow-up Study. Am J Epidemiol (1990) 0.88
Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation (1998) 0.87
Estrogen replacement and coronary heart disease. Cardiovasc Clin (1989) 0.87
Regulation of polyamine biosynthesis in rat hepatoma (HTC) cells by a bisbenzyl polyamine analogue. Biochem J (1989) 0.86
Media coverage of women's health issues: is there a bias in the reporting of an association between hormone replacement therapy and breast cancer? J Womens Health Gend Based Med (2001) 0.85
Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev (1991) 0.85
Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res (1995) 0.84
Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Control Clin Trials (1995) 0.83
Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res (1994) 0.83
Physical activity and fracture risk in a free-living elderly cohort. J Gerontol (1988) 0.82
Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Arterioscler Thromb Vasc Biol (1995) 0.82
The Washington County Training Center: an exemplar of public health research in the field. Am J Epidemiol (1991) 0.81
The potential role of respiratory therapy equipment in cross infection. A study using a canine model for pneumonia. Am Rev Respir Dis (1983) 0.80
In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res (1996) 0.79
Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells. Biochem Pharmacol (1998) 0.79
Breast cancer mortality in black and in white women: a historical perspective by menopausal status. J Womens Health (1998) 0.78
Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer (2000) 0.78
Direct depletion and purification of monoclonal antibody defined cells from unfractionated human mononuclear leukocytes using antibody coated polystyrene Petri dishes. J Clin Lab Immunol (1984) 0.78
Effects of raloxifene in postmenopausal women. N Engl J Med (1998) 0.77
Measurement of mRNA levels in tumor xenografts with quantitative autoradiography and in situ hybridization. FASEB J (1995) 0.77
Estrogen replacement therapy and risk of breast cancer. JAMA (1991) 0.76
Estrogen therapy and cardiovascular risk in women. J La State Med Soc (1991) 0.76
Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy. Am J Hematol (1999) 0.76
Breast cancer and hormone-replacement therapy. N Engl J Med (1995) 0.75
Women's perception of risk of coronary artery disease. J Womens Health (1997) 0.75
Racial differences in breast cancer mortality. Arch Fam Med (2000) 0.75
SERMs: the benefits of estrogen without the risks? J Womens Health (1998) 0.75
Oestrogen therapy and cardiovascular disease: do the benefits outweigh the risks? Baillieres Clin Obstet Gynaecol (1991) 0.75
Lessons from HERS: the null and beyond. J Womens Health (1998) 0.75
Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731). Oncol Res (1997) 0.75
The adverse effects of hormonal therapy. Cardiol Clin (1986) 0.75
Agreement in assessing endometrial pathology: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health (1998) 0.75
Racial differences in drug metabolism: an explanation for higher breast cancer mortality in blacks? Med Hypotheses (1998) 0.75
The distribution of fasting plasma glucose in a rural population: The Oklahoma lipid research clinic program. J Okla State Med Assoc (1982) 0.75
Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma. Anticancer Res (1996) 0.75
Dietary intake in rural Oklahomans. J Okla State Med Assoc (1983) 0.75
Putting names to faces: another potential promise of estrogen replacement therapy? J Am Geriatr Soc (1994) 0.75
Quality of life among the elderly in Veneto, Italy: a cross-sectional study. Vital Health Stat 5 (1991) 0.75